Bone Solutions, Onkos ink private label deal

Bone Solutions said today that it entered into a private label licensing agreement with Onkos Surgical for its OsteoCrete bone void-filling technology.

Colleyville, Texas-based BSI’s OsteoCrete is an FDA 510(k)-cleared magnesium-based injectable, moldable solution designed to attaching ligaments and tendons to bone and bone to bone. Parsippany, N.J.-based Onkos Surgical intends to market OsteoCrete under the GenVie brand.

Earlier this month BSI agreed to a private label distribution deal with WishBone Medical, granting WishBone worldwide rights to OsteoCrete for pediatric indications, reporting more than 600 cases implanting OsteoCrete this year.

“For so many years, the orthopedics industry demonstrated a clear demand for osteogenic implants which mimic properties of the human bone,” BSI president & CEO Drew Diaz said in prepared remarks. “Prior to OsteoCrete, calcium-based solutions contributed to bone healing, but with little extended mechanical support. Not only is OsteoCrete resorbable – it offers excellent bone remodeling during the window of healing with uncompromised strength.”

“We are excited to partner with Bone Solutions and the OsteoCrete technology platform,” added Onkos CEO Patrick Treacy. “The properties of this unique formulation provide an ideal strength and resorption profile that our customers are looking for. The demands of our patient population require a product that provides a consistent and predictable healing window. We believe the magnesium-based phosphate technology provides an elegant solution for use in certain tumor and complex revision cases and we will plan on launching this product in the coming months under our GenVie brand.”